Nevertheless, further comprehensive studies are necessary to fully comprehend the involvement of lncH19 in the molecular pathways associated with DN, as well as explore the potential therapeutic effects of inhibiting lncH19 and the interaction with VEGFA in DN patients. This evidence concerns the gene VEGFA and liver dysplastic nodule.